SCHEMBL20203477

SCHEMBL20203477

CSc1ncc2cc(C(F)F)nc(-c3ccccc3C)c2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.36
HSP90AA1 P07900 1/20 0.36
AURKA O14965 1/20 0.36
AURKB Q96GD4 1/20 0.36
HASPIN Q8TF76 2/20 0.36
RXFP1 Q9HBX9 3/20 0.34
NTRK1 P04629 1/20 0.33
HSP90AB1 P08238 2/20 0.33
NPC1 O15118 1/20 0.33
DCUN1D1 Q96GG9 1/20 0.33
MAPT P10636 2/20 0.32
LCK P06239 1/20 0.32
JAK3 P52333 1/20 0.32
MAPK14 Q16539 1/20 0.32
HTT P42858 1/20 0.32
TRPA1 O75762 1/20 0.31
ATM Q13315 1/20 0.31
TP53 P04637 1/20 0.31
POLB P06746 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20203625 0.75 HASPIN (0.35) HASPIN
SCHEMBL30768115 0.73 HASPIN (0.39) HASPINHTT
SCHEMBL26341306 0.73 HASPIN (0.39) HASPINHTT
SCHEMBL20203622 0.71 TDP1 (0.35) HASPINNPC1JAK3
SCHEMBL20203618 0.70 TDP1 (0.39) RXFP1NTRK1NPC1MAPTTP53
SCHEMBL6016289 0.70 NTRK1 (0.47) KDRHSP90AA1AURKAAURKBRXFP1
SCHEMBL20037627 0.69 HASPIN (0.36) HASPIN
SCHEMBL1325422 0.69 HSP90AA1 (0.37) KDRHSP90AA1AURKAAURKBHASPIN
SCHEMBL26341595 0.69 HASPIN (0.31) HASPIN
SCHEMBL26181506 0.68 HASPIN (0.35) HASPIN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 US disclosed
EP-3546458-B1 ((PYRIDIN-2-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE AND ((PYRIDAZIN-3-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES AS CDK4/6 INHIBITORS FOR TREATING E.G. RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, PULMONARY FIBROSIS, CEREBRAL INFARCTION OR CANCER TEIJIN PHARMA LTD (JP) 2021-01-06 EP disclosed
WO-2018097297-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 帝人ファーマ株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof CDK4, CDK6, CDK16 KDR 1105/4885HSP90AA1 4289/4885AURKA 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.